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Abstract 
Background/aims: The identification of Lynch syndrome is hampered by the absence of 
specific diagnostic features and underutilization of genetic testing. Prediction models have 
therefore been developed, but they have not been validated for a clinical genetic setting. The 
aim of the present study was to evaluate the usefulness of currently available prediction 
models. 
Methods: We collected data of 321 index probands who were referred to the department of 
Clinical Genetics of the Erasmus Medical Center because of a family history of colorectal 
cancer. These data were used as input for five previously published models. External validity 
was assessed by discriminative ability (AUC: area under the receiver operating characteristic 
curve) and calibration. For further insight, predicted probabilities were categorized with cut-
offs of 5%, 10%, 20% and 40%. Furthermore, costs of different testing strategies were related 
to the number of extra detected mutation carriers. 
Results: Of the 321 index probands, 66 harboured a germline mutation. All models 
discriminated well between high risk and low risk index probands (AUC: 0.82-0.84). 
Calibration was well for the Premm1,2 and Edinburgh model, but poor for the other models. 
Cut-offs could be found for the prediction models where costs could be saved while missing 
only few mutations.  
Conclusions: The Edinburgh and Premm1,2 model were the models with the best performance 
for an intermediate to high-risk setting. These models may well be of use in clinical practice 
to select patients for further testing of mismatch repair gene mutations.
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INTRODUCTION 
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer, is the most 
common form of hereditary colorectal cancer (CRC). This syndrome is characterized by early 
onset of CRC and endometrial cancer. In addition, tumours of the stomach, small bowel, 
urinary tract, ovaries, brain and skin occur at higher frequencies in Lynch syndrome families 
compared to the general population.[1, 2] Lynch syndrome is caused by mutations in the 
mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2). As a consequence, Lynch 
syndrome-associated tumours exhibit microsatellite instability (MSI) and absent protein 
expression of the affected gene. Early identification of mutation carriers is important because 
of the high risk for colorectal cancer and other malignancies.  
Identification of mutation carriers can be based on a combination of clinical diagnostic 
criteria, the Amsterdam II criteria (AC II) and the revised Bethesda guidelines (BG).[3, 4] The 
AC II, however, have a limited sensitivity for the detection of mutation carriers and therefore 
it is suboptimal for identification of mutation carriers. The BG were therefore developed to 
identify individuals eligible for molecular screening by microsatellite instability (MSI) and 
immunohistochemical (IHC) staining of MMR proteins. However, some components of the 
BG are rather complex. Molecular screening by MSI testing and IHC staining of proteins has 
a higher sensitivity compared to the AC II and BG [5-11] but MSI with absent staining of 
MLH1 and PMS2 is also present in 15% of sporadic CRC cases.[12-14] Furthermore, MSI 
and IHC analysis can only be performed when tumour tissue is available. The optimal 
diagnostic strategy for Lynch syndrome is still under debate. Performing MSI and IHC in 
CRC cases selected by the pathologists has been proposed as a diagnostic strategy by some 
authors[9, 15, 16], while others propose fulfilment of BG followed by MSI and IHC analysis 
as a more effective strategy.[10] These different views emphasize the need for other 
diagnostic tools in the identification of Lynch syndrome.  
In recent years, several models have been developed to predict the likelihood of carrying a 
germline mutation.[11, 17-20] These models use information from personal and family 
history as input to predict the probability of mutation carriership. A major advantage of 
prediction models is that these models give a quantitative estimate instead of a binary (yes/no) 
assessment as provided by the clinical diagnostic criteria. Mutation prediction models are thus 
potentially useful in clinical practice to optimise the identification of Lynch syndrome 
carriers, but the performances of these models have not been evaluated other than in similar 
settings as where they were developed. External validation is necessary to study 
generalizability of these models. Moreover, we need to consider the cut-off that should be 
used to select patients for further evaluation for Lynch syndrome. For example, a cut-off of 
5% may be preferable to 10% if the additional costs of testing patients with risks between 5% 
and 10% are reasonable compared to the detection of some extra mutation carriers in this 
group.  
The aim of the present study was to evaluate the usefulness of five easily applicable mutation 
prediction models in a clinical population of familial CRC. 
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METHODS 
Study population 
Since 1992 high-risk families for Lynch syndrome have been referred by general practitioners 
and medical specialists to the department of Clinical Genetics of the Erasmus MC University 
Medical Center for oncogenetic counselling. We included families with one or more subjects 
who had undergone cancer risk assessment for Lynch syndrome. From every family one or 
more family members underwent tumour analysis by MSI and IHC analysis, and /or 
underwent germline mutation analysis for mutations in the MLH1, MSH2 and MSH6 genes. In 
total, 321 unrelated families with 17552 members were included in this study. 
In every family, an index proband was identified, defined as the youngest family member 
diagnosed with CRC and in which MSI, IHC analysis and/or germline mutation analysis had 
been performed. Demographic, clinical and tumour related characteristics of the index 
proband and a detailed family history were obtained from medical records and family 
pedigrees. Only findings that were confirmed by pathology or medical records were included. 
Family pedigrees were traced backwards and laterally as far as possible, at least to second-
degree relatives. For all the affected individuals the age of cancer onset, type, location, 
tumour stage of the malignancy, the presence and number of colorectal adenomas and results 
of MSI, IHC and/or germline mutation analysis were recorded. Furthermore, the presence and 
number of colorectal adenomas and the results of germline mutation analysis in healthy 
individuals was recorded. We defined synchronous colorectal cancers as a second primary 
cancer diagnosed within 6 months and metachronous colorectal cancers as a second primary 
cancer, diagnosed at least 6 month after the primary cancer.  
 
Molecular screening 
MSI analysis was performed on paired tumour and normal tissue DNA using a panel of 5 
validated microsatellite markers, as described previously.[21] Tumours were regarded as 
MSI-high if at least two of the five markers showed instability, MSI-low if one of the five 
markers showed instability and MSI-stable if none of the markers showed instability. 
Immunostaining for MLH1, MSH2 and MSH6 was carried out as described previously.[21] 
The slides were scored as either negative (i.e. the absence of detectable nuclear staining of 
cancer cells), or positive for MLH1, MSH2 and MSH6 staining. Individuals found to have 
tumours with either an MSI-high phenotype or lack of MLH1, MSH2 or MSH6 protein 
expression were considered MMR deficient, while individuals with a tumour exhibiting an 
MSI-stable phenotype with normal MLH1, MSH2 or MSH6 protein expression were 
considered MMR proficient. 
 
Germline mutation analysis 
All individuals with a MMR deficient tumour underwent germline mutation analysis of the 
MLH1, MSH2 and MSH6 gene. Germline mutation analysis was performed by sequencing and 
Multiplex Ligation-dependent Probe Amplification (MRC Holland).  
 
Classification of index probands 
Index probands were considered positive if germline mutation analysis revealed a mutation in 
one of the mismatch repair genes. Index probands in whom germline mutation analysis 
detected an unclassified variant or no mutation were classified as non-mutation carrier.  
Index probands in which only MSI and IHC analysis had been performed and the analysis 
showed a MMR proficient tumour were also classified as non-mutation carrier.   
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Prediction models 
Mutation probability estimates for MLH1, MSH2 and MSH6 were calculated using five, 
previously published prediction models, i.e. the Leiden[11], PREMM1,2[19], Edinburgh[18], 
UK-Amsterdam Plus (UK-Ams)[17], and UK-Alternative (UK-Alt) model[17]. 
The Leiden and PREMM1,2 model predict the likelihood of finding an MLH1 or MSH2 gene 
mutation, while the Edinburgh, UK-Ams and UK-Alt model predict the likelihood of finding 
a MLH1, MSH2 or MSH6 gene mutation in high risk individuals (Table 1).  
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Table 1. Input variables and features of the five prediction models. 
 
CRC = colorectal cancer 
EC = endometrial carcinoma   
†
 For the UK-Ams and UK-Alt only counselees and relatives with > 5 colonic adenomas are included. 
‡
 For the UK-Ams and UK-Alt only individuals with syn- / metachronous CRC and EC are included. 
Variable Leiden 
[11] 
Premm1,2  
[19] 
Edinburgh  
[18] 
UK-Ams 
[17] 
UK-Alt 
[17] 
      
Model input      
Gender counselee   x   
CRC status counselee x x x x x 
CRC status relatives x x x x x 
No. of CRC in counselee  x  x x 
No. of relatives with CRC  x  x x 
CRC age of onset counselee x x x x x 
CRC age of onset relatives x x x x x 
EC status counselee x x x x x 
EC status relatives x x x x x 
No. of relatives with EC x   x x 
EC age of onset counselee  x  x x 
EC age of onset relatives  x  x x 
Colonic adenoma status 
counselee 
 x  x
†
 x
†
 
Colonic adenoma status 
relatives 
   x
†
 x
†
 
No. of relatives with colonic 
adenoma 
   x
†
   x
†
 
Lynch syndrome associated 
cancer status 
counselee 
 
 
 
x 
   
Lynch syndrome associated 
cancer status 
relatives 
  
x 
   
Fulfilment of Amsterdam II 
criteria 
x   x  
Presence of syn- / metachronous 
cancer 
  x x
‡
 x
‡
 
Proximal location CRC   x   
      
Model output      
Predictions for carrying a MLH1 
or MSH2 mutation  
x x    
Predictions for carrying a 
MLH1, MSH2 or MSH6  
  x x x 
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Cost effectiveness analysis 
We estimated the costs and effects (number of detected mutations) of different diagnostic 
strategies. The costs of tumour MMR deficiency (MSI and IHC) testing were estimated as € 
590, the tariff recommended by the Dutch Pathology association (www.pathology.nl). The 
costs of germline mutation analysis were assumed to be  € 620 for each MMR gene.[22] In 
case of direct germline mutation analysis, three MMR genes have to be analysed, thus the 
costs associated with this strategy was € 1,860. Tumour MMR deficiency analysis is mostly 
indicative for the mutated MMR gene and therefore the costs of subsequent germline mutation 
analysis was calculated for a single MMR gene (€ 620). Costs were related to the number of 
mutations detected in MLH1, MSH2, or MSH6 genes for all prediction models. The 
diagnostic strategies included: i) direct germline mutation analysis in all index probands, ii) 
tumour MMR deficiency analysis in all index probands followed by germline mutation 
analysis in those with MMR deficient tumours and iii) a strategy in which prediction models 
were used to select cases eligible for additional tumour MMR deficiency analysis and 
subsequent germline mutation analysis. Strategy iii considered consecutive cut-off values for 
the predicted probability of a mutation of each prediction model, such that incremental cost-
effectiveness could be calculated, expressed as extra costs (k€ = thousands of Euro) per extra 
detected mutation. 
 
Statistical analysis 
Sensitivity and specificity were calculated for the five different models with respect to the 
presence of a MLH1, MSH2, or MSH6 germline mutation, considering cut-offs for the 
predicted probability of a mutation of 5%, 10%, 20% and 40%. The predicted probabilities for 
each index proband included in the study were calculated using an extensive coding program 
in the SPSS software package (version 12.0.1, SPSS Inc, Chicago, IL), with verification in an 
independently developed Microsoft Excel spreadsheet (Microsoft Corporation, Redmond, 
WA). The performance of the models was assessed with respect to discrimination and 
calibration. Discrimination is the model’s ability to separate patients with and without 
mutations. To quantify discrimination, the area under the receiver operating characteristic 
curve (AUC) was calculated. A model with an AUC of 0.50 has no discriminative power, 
while an AUC of 1.0 reflects perfect discrimination. Calibration reflects the ability of a model 
to produce unbiased estimates of the probability of an outcome. For example, if patients with 
certain characteristics are predicted to have a 10% chance of carrying a mutation, the 
observed prevalence of mutation carriership should also be 10%. Calibration was assessed 
graphically by plotting observed outcome against the predicted probability (0%-100%). 
Calibration was further tested with the Hosmer-Lemeshow goodness-of-fit test.[23] For the 
five models we compared observed outcome vs. predicted risks for each decile. 
Discrimination and calibration were calculated using R software (Version 2.5.1, the R 
Foundation for Statistical Computing). All p-values were two sided and a p-value of less than 
0.05 was considered statistically significant. 
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RESULTS 
Index proband characteristics 
A total of 321 unrelated index probands (155 male / 166 female) of 321 families were 
included in this study (Table 2).  
 
Table 2. Family history and index probands characteristics (n=321) 
Characteristics MLH1 
mutation 
MSH2 
mutation 
MSH6 
mutation 
No 
mutation 
Total 
 n (%) n (%) n (%) n (%) n (%) 
 
     
Mutation status 25  23 18 255  321  
 
     
Family history 
     
No. of CRC 65  64  41 426  596  
No. of EC 13  13  23 5 54  
No. of other LS-associated cancer 7 16 6 63  92  
 
     
Amsterdam II criteria +* 7 (28) 9 (39) 4 (22) 7 (3) 27 (8) 
Revised Bethesda guidelines +* 21(84) 21 (91) 9 (50) 104 (41) 155 (48) 
 
     
Proband characteristics 
     
Male gender 11 (44) 10 (43) 8 (44) 126 (49) 155 (48) 
 
     
Mean age CRC onset (yrs ± SD ) 44 (± 11) 30 (± 11) 52 (± 14) 54 (±13) 51 (± 13) 
Mean age EC onset (yrs ± SD) 51 (± 4) 49 (± 4) 57 (± 5) 52 (± 5) 53 (± 6) 
 
     
Site of tumour 
     
        Proximal  22 (88) 16 (70) 10 (56) 66 (26) 114 (36) 
 
     
Synchronous CRC 4 (16) 6 (26) 1 (6) 9 (4) 20 (6) 
 
     
First degree relative with CRC 
     
0 relatives 11 (44) 11 (48) 10 (56) 161 (63) 193 (60) 
1 relative 8 (32) 8 (35) 5 (28) 81 (32) 102 (32) 
≥ 2 relatives 6 (24) 4 (17) 3 (16) 13 (5) 26 (8) 
      
MMR deficient tumour† 9/9 7/7 11/11 27/250 54/277 
 
CRC = colorectal cancer 
EC = endometrial cancer 
LS = Lynch syndrome 
SD = standard deviation 
 
* fulfilling the Amsterdam II criteria or the revised Bethesda guidelines 
†
 defined as MSI-high phenotype or loss of MLH1, MSH2 or MSH6 protein expression by 
immunohistochemistry  
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Twenty-seven (8%) and 155 (48%) of them met the Amsterdam II criteria and Bethesda 
guidelines respectively. Among the MLH1 and MSH2 mutation carriers, the BG were positive 
in respectively 84% and 91%. Among the MSH6 mutation carriers, the BG were positive in 
only 50%. The index probands were primarily analysed by MSI and IHC (n=277; 86%) or by 
direct germline mutation analysis (n=44; 14%). Of the 277 (86%) index probands who 
underwent molecular analysis by MSI and IHC, 54 (19%) index probands had a tumour 
demonstrating MMR deficiency. Germline mutation analysis was performed in 175 (55%) 
index probands, 54 (31%) with an MMR deficient tumour, 77(44%) with an MMR proficient 
tumour and 44 (25%) who directly underwent germline mutation analysis. In total, 66 
mutations in either MLH1 (n=25; 38%), MSH2 (n = 23; 35%) or MSH6 (n= 18; 27%) were 
identified. In 146 (45%) index probands only MSI and IHC analysis was performed which 
showed an MMR proficient tumour. These index probands were considered as non-mutation 
carriers. 
 
Detection of mutations 
The AC II had a sensitivity for identification of mutation carriers of 30% (20/66) and a 
specificity of 89% (228/255). The BG missed 15 of the 66 mutation carriers, corresponding 
with a sensitivity of 77% and a specificity of 59% (151/255). Molecular analysis with MSI 
and IHC in tumours of 277 index probands identified 54 (19%) index probands with a MMR 
deficient tumour, corresponding with a sensitivity of 100% and a specificity of 89% for 
detection of mutation carriers. 
 
Performance of prediction models 
All prediction models discriminated well between high risk and low risk probands, with an 
AUC of 0.82 for the UK-Ams and UK-Alt model and an AUC of 0.84 for the Leiden, 
Premm1,2 and Edinburgh model. Calibration curves showed considerable differences between 
observed mutation frequency and predictions from the Leiden, UK-Ams and UK-Alt models 
(Figure 1, Hosmer-Lemeshow goodness of fit test p< 0.0001). For example, the calibration 
curve in the Leiden model was above the dotted ideal line. This implies that most predicted 
probabilities for mutation carriership were systematically too low; for example index 
probands with a predicted probability of 40% actually had an observed probability for a 
mutation carriership around 70%.  
Using a probability cut-off value of ≥ 5%, the UK-Alt model identified all mutation carriers, 
corresponding with a sensitivity of 100% (Table 3). The 100% sensitivity of the UK-Alt 
model is explained by the fact that the predicted probabilities were systematically too high, as 
shown in Figure 1. The two well-calibrated models, the Premm1,2 and Edinburgh, both had a 
sensitivity of 98% at a 5% cut-off. The specificity of both models at a 5% cut-off was 22% 
and 9%, respectively. The Leiden model had the lowest sensitivity at a 5% cut-off (73%) and 
the highest specificity (80%), which relates to systematic underestimation of actual 
frequencies of mutations (Fig 1). Using cut-off values of 10% or above resulted in a 
progressive loss of sensitivity of all the models (Table 3). 
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Table 3. Performance characteristics of the prediction models according to different strategies  
Model  Without MMR 
deficiency analysis 
With MMR  
deficiency analysis* 
 Sensitivity (%) Specificity (%) Specificity (%) 
 
   
Leiden model    
≥ 5% 73 80 80 
≥ 10% 58 90 89 
≥ 20% 38 98 100 
≥ 40% 27 99 100 
    
Premm1,2 model    
≥ 5% 98 22 82 
≥ 10% 88 67 87 
≥ 20% 67 84 86 
≥ 40% 29 94 87 
    
Edinburgh model    
≥ 5% 98 9 90 
≥ 10% 94 29 90 
≥ 20% 83 69 90 
≥ 40% 53 96 89 
    
UK-Ams model    
≥ 5% 82 55 89 
≥ 10% 76 80 84 
≥ 20% 56 95 93 
≥ 40% 38 99 100 
    
UK-Alt model    
≥ 5% 100 13 90 
≥ 10% 91 24 91 
≥ 20% 77 60 89 
≥ 40% 65 91 87 
 
 *  The sensitivity was calculated for 66 mutation carriers; specificity without MMR deficiency 
analysis for 255 index probands without mutation. The specificity with MMR deficiency analysis was 
calculated for 250 index probands without mutation among the 277 index probands who underwent 
tumour MMR deficiency analysis. 
 
 
 
 on 30 July 2009 jmg.bmj.comDownloaded from 
 11
As expected, the combination of prediction models with subsequent MMR deficiency analysis 
before MMR mutation testing increased the specificity associated with each model. For 
example, at a 5% cut-off the specificity of the Premm1,2 model increased from 22% to 82%. 
 
Cost effectiveness of different diagnostic strategies 
The most expensive diagnostic strategy was direct germline mutation analysis in all index 
probands (k€ 597 or k€ 9,1 per mutation). Performing tumour MMR deficiency analysis in all 
index probands followed by germline mutation analysis in those with a MMR deficient 
tumour was less expensive (k€ 248, k€ 3,8 per mutation, Table 4). 
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Table 4. Cost effectiveness of the prediction models at different cut-off values.        
                  
 MMR deficiency  
analysis (n) 
Germline mutation  
analysis (n) 
Total costs Mutations detected 
(n) 
Costs per extra 
detected mutation 
MMR deficiency analysis 321 94 € 247,670 66 NA 
 
     
Leiden model      
≥ 0% 321 94 € 247,670 66 € 7,112 
≥ 5% 90 50 €   84,100 43 € 2,871 
≥ 10% 55 37 €   55,390 33 € 2,351 
≥ 20% 24 21 €   27,180 21 € 1,505 
≥ 40% 15 15 €   18,150 15 € 1,210 
      
Premm1,2 model      
≥ 0% 321 94 € 247,670 66 € 20,475 
≥ 5% 260 86 € 206,720 64 €   8,331 
≥ 10% 132 60 € 115,080 53 €   3,831 
≥ 20% 73 42 €   69,110 41 €   1,724 
≥ 40% 31 18 €   29,450 18 €   1,636 
      
Edinburgh model      
≥ 0% 321 94 € 247,670 66 € 16,640 
≥ 5% 297 90 € 231,030 65 € 37,410 
≥ 10% 242 82 € 193,620 62 € 10,524 
≥ 20% 135 65 € 119,950 55 €   3,554 
≥ 40% 45 36 €   48,870 35 €   1,396 
      
UK-Ams model      
≥ 0% 321 94 € 247,670 66 €   8,819 
≥ 5% 170 67 € 141,840 54 € 11,270 
≥ 10% 102 59 €   96,760 50 €   3,316 
≥ 20% 51 38 €   53,650 37 €   1,852 
≥ 40% 27 25 €   31,430 25 €   1,257 
      
UK-Alt model      
≥ 0% 321 94 € 247,670 66 ∞ 
≥ 5% 288 89 € 225,100 66 € 4,372 
≥ 10% 253 80 € 198,870 60 € 7,796 
≥ 20% 153 62 € 128,710 51 € 7,656 
≥ 40% 66 46 €   67,460 43 € 1,569 
 
NA = not applicable 
 o
n
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Using prediction models to select cases for additional tumour MMR deficiency analysis and 
subsequent germline mutation analysis was associated with lower costs, at the expense of 
missing mutations. At a 5% cut-off, the Leiden model was associated with the lowest costs  
(k€ 84), but 23 mutations would be missed. To detect all mutations, the extra costs per extra 
detected mutation were k€ 7. The Edinburgh and Premm1,2 models detected nearly all 
mutations at a 5% cut-off (65/66 and 64/66 respectively). To detect the one or two missed 
mutations would cost an additional k€ 16 or k€ 20 respectively. With a cut-off of 10%, three 
(65-62) or 11 (64-53) more mutations would be missed. The extra costs were k€ 37 and  
k€ 8 per extra mutation for the Edinburgh and Premm1,2 model respectively. A cut-off of 20% 
would lead to many more mutations missed (62-55 = 7 and 53-41 = 12 respectively), with costs 
of k€ 11 and k€ 4 per extra detected mutation. A cut-off of 5% for the Premm1,2 model hence 
had a similar cost-effectiveness as a threshold of 10% for the Edinburgh model, which is 
related to the slight difference in calibration at low predicted probabilities (Figure 1). 
Accepting a threshold for the costs per extra detected mutation of approximately k€ 10, would 
result in the use of different cut-off values. The Leiden and UK-Ams model should be used 
with a cut-off value less than 5%, the UK-Alt and Premm1,2 model with a ≥ 5% cut-off and the 
Edinburgh model with a cut-off value of ≥ 10%
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DISCUSSION 
Identification of high-risk subjects  at high risk for Lynch syndrome still remains difficult. In 
this study we found adequate discriminative ability of five different mutation prediction 
models for Lynch syndrome using clinical data of 321 index probands with suspicion of Lynch 
syndrome. Among the five models considered, the Premm1,2 and Edinburgh model had the best 
performance in predicting mutation carriership, because these two models had the highest 
discriminative ability and were well calibrated. Combining prediction models with tumour 
MMR deficiency analysis resulted in a substantial increase of the specificity.  
The calibration of the Leiden, UK-Ams and UK-Alt models was relatively poor, reflecting that 
predicted probabilities were systematically too high or too low. Although the Edinburgh model 
was developed using population-based data, this model was well calibrated in our intermediate 
to high-risk population. The Premm1,2 model and the Leiden model were designed to predict 
only the presence of MLH1 and MSH2 mutations. Recently, the Premm1,2 model was evaluated 
in a population based cohort of 1222 colorectal cancer patients, and identified all MLH1 and 
MSH2 mutation carriers.[24] However, the number of identified mutations (n=8) was very low, 
limiting the strength of the conclusions from this study. 
 
In subjects suspected of Lynch syndrome, high sensitivity is important to identify mutation 
carriers. Tumour MMR testing in all by definition has the highest sensitivity (100%), but the 
lowest specificity (0%). This strategy was associated with high costs. Therefore, selection of 
high-risk individuals may be considered. The low sensitivity of the AC II and the complexity 
of the BG necessitate new diagnostic strategies to identify individuals at risk for Lynch 
syndrome. Prediction models have a higher sensitivity compared to the AC II and BG if 
relatively low cut-offs are used for the predicted probability of mutation. With cut-offs of 5% 
to 10% such models can well be useful in a clinical setting. External validation showed that 
especially the Premm1,2 and Edinburgh model were accurate in predicting mutation carriership, 
with a sensitivity of 98% at a 5% cut-off. Although the number of variables in the Edinburgh 
model is only half of those in the UK-Ams and UK-Alt, the Edinburgh model performed better 
in our study population. The difference in performance between models can largely be 
explained by the difference in included predictors. In clinical practice, the Premm1,2 and 
Edinburgh model can be used to identify high-risk individuals who are eligible for tumour 
MMR deficiency analysis.  
Using prediction models led to lower costs than tumour MMR deficiency analysis in all CRC 
cases at the expensive of missing no or only few mutation carriers. The cost-effectiveness is 
determined by the cut-off value used, with lower cut-off values resulting in higher costs per 
extra detected mutation. The optimal threshold in terms of cost-effectiveness is not known and 
may depend on the specific health care setting. One might accept high costs per extra detected 
mutations when proven mutation carriers will follow colonoscopic surveillance. Such 
surveillance is highly effective in Lynch syndrome. A 25-year-old person would gain 13.5 
years of life expectance compared to no surveillance.[25, 26] The reported compliance in 
mutation carriers is approximately 90%, thus the expected gain in life expectancy may be only 
slightly less.[27] Further establishment of the optimal threshold in terms of cost effectiveness 
and life years gained is needed. We note that the availability of user-friendly formats, such as 
the web-based Premm1,2 model (http://www.dana-farber.org/pat/cancer/gastrointestinal/crc-
calculator/), enables easy calculation of predicted probabilities in clinical practice.  
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Our study population consisted of families that had been counselled at the department of 
clinical genetics, including the use of ‘family forms’, where all family members were noted by 
name, gender and birth date, and family members affected by cancer were noted. This enabled 
further verification of the family history by medical records and pathology reports. The family 
history was hence as complete as possible which can be considered as strength of our study. 
But the results of this study may not apply to the performance of mutation prediction models in 
the general population, because we used an intermediate to high-risk study population. Another 
limitation of our study was that not all probands underwent germline mutation analysis. We 
classified the probands with normal tumor MMR results and in whom no germline mutation 
analysis was performed as non-mutation carriers. Theoretically, these probands could harbour 
a mutation. However, the reported sensitivity of both MSI (80%-100%) and IHC analysis (85-
95%) are high.[8-10, 18, 28-30] Finally, we only evaluated logistic regression based prediction 
models and therefore excluded the MMRpro model. MMRpro is a Mendelian model, which 
uses Bayesian calculations considering information from the full pedigree, including 
unaffected relatives. The performance of MMRpro may be similar to the Edinburgh and 
Premm1,2 models in the clinical setting, but further evaluation is needed.  
 
In conclusion, we have evaluated five easily applicable mutation prediction models for Lynch 
syndrome in a selected clinical population. The models have a high accuracy and cost-
effectiveness for detecting germline mutations in the mismatch repair genes. The Edinburgh 
and Premm1,2 model had the best performance in an intermediate to high-risk setting and these 
models may well be of use in clinical practice. The poor calibration of the Leiden, UK-Ams 
and UK-Alt model hampers direct application of these mutation prediction models. Further 
evaluation of mutation prediction models across different settings is needed.  
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Legend 
Figure 1. Validation of the five mutation prediction models.  
The smooth curves reflect the relationship between observed fraction with a mutation and 
predictions from each model. Perfect calibration is represented by the straight dotted line 
through the origin. Triangles indicate the fraction of mutations in quintiles of patients with 
similar predictions, with 95% confidence intervals. Spikes at the bottom of each graph 
represent the distribution of predictions for those with and without mutations respectively. 
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